Freeslate, Inc. has entered into a strategic partnership with Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD, LLC.) to deliver integrated workflows, software, and pharmaceutical research services thru 2012. These products and services are specifically designed to deliver step-change gains in productivity and innovation, impacting both large and small molecule drug development.
“This strategic partnership demonstrates both the breadth and depth of Freeslate’s expertise in deploying industry-leading solutions to pharmaceutical research organizations,” said John Senaldi, chief executive officer of Freeslate. “We are excited to further our success in helping our customers make better decisions earlier in the drug development process.”
Freeslate’s new workflow tools are built on its recently-launched, modular CM3 platform to impact small molecule drug product development, biological drug substance development, and biological formulation development and testing. In addition to delivering Freeslate’s Laboratory Execution and Analysis (LEA) software to power these tools, the company will be deploying the LEA suite of software to integrate a number of existing workflows.
